Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NKT3447 |
Synonyms | |
Therapy Description |
NKT3447 selectively inhibits CDK2 and disrupts the CDK2/CCNE1 and CDK2/CCNA2 complexes, which results in decreased Ccne1 and inhibition of Rb1 phosphorylation, potentially leading to cell cycle arrest and inhibition of tumor growth (Cancer Res (2024) 84 (6_Supplement): 5705). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NKT3447 | NKT-3447|NKT 3447 | CDK2 Inhibitor 31 | NKT3447 selectively inhibits CDK2 and disrupts the CDK2/CCNE1 and CDK2/CCNA2 complexes, which results in decreased Ccne1 and inhibition of Rb1 phosphorylation, potentially leading to cell cycle arrest and inhibition of tumor growth (Cancer Res (2024) 84 (6_Supplement): 5705). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06264921 | Phase I | NKT3447 | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors | Recruiting | USA | 0 |